Zenflow
Minimally-invasive approach to treating benign prostatic hyperplasia (BPH) or enlarged prostate.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | $24.0m Valuation: $157m | Series C | |
| Total Funding | 000k | ||
Related Content
Zenflow is a medical device company that has developed the Spring® System, a minimally invasive treatment for men suffering from an enlarged prostate, also known as benign prostatic hyperplasia (BPH).
The company's approach is to provide a long-term solution that avoids the side effects and risks associated with medications and more invasive surgical procedures. The Spring® System is designed to be a straightforward, office-based procedure that can be completed in a short amount of time, allowing patients to recover quickly and resume their normal activities.
Zenflow is currently in the process of seeking regulatory approval for its device. The company has completed a pivotal clinical trial, the BREEZE study, and is using the results to support its application to the U.S. Food and Drug Administration (FDA) for pre-market approval. To fund this process and prepare for the commercial launch of the Spring® System, Zenflow has recently secured $24 million in a financing round.
Keywords: medical devices, urology, BPH treatment, minimally invasive surgery, healthcare, men's health, medical technology, surgical devices, clinical trials, FDA approval